COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

• Published in: Blood advances 2021-02, Vol.5 (3), p.861-871
• Main Authors: Maurer, Katie, Saucier, Anna, Kim, Haesook T., Acharya, Utkarsh, Mo, Clifton C., Porter, Julie, Albert, Cindy, Cutler, Corey, Antin, Joseph H., Koreth, John, Gooptu, Mahasweta, Romee, Rizwan, Wu, Catherine J., Soiffer, Robert J., Nikiforow, Sarah, Jacobson, Caron, Ho, Vincent T.
• Format: Article
• Language: English
• Subjects: Adult; Aged; COVID-19 - mortality; COVID-19 - pathology; COVID-19 - therapy; COVID-19 - virology; Female; Graft vs Host Disease - etiology; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; SARS-CoV-2 - isolation & purification; Transplantation; Transplantation, Autologous; Transplantation, Homologous; United States; Young Adult
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2020003883

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified in late 2019 as the causative agent of COVID-19, was declared a pandemic by the World Health Organization on 11 March 2020. Widespread community transmission in the United States triggered a nationwide shutdown, raising major challenges for administration of hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR)-T cell therapies, leading many centers to delay or cancel operations. We sought to assess the impact of the COVID-19 pandemic on operations and clinical outcomes for HSCT and CAR-T cellular therapies at the Dana-Farber Cancer Institute by reviewing administration and outcomes in 127 cell therapy patients treated during the initial COVID-19 surge: 62 adult allogeneic HSCT (allo-HSCT), 38 autologous HSCT (auto-HSCT), and 27 CAR-T patients. Outcomes were compared with 66 allo-HSCT, 43 auto-HSCT, and 33 CAR-T patients treated prior to the pandemic. A second control cohort was evaluated for HSCT groups to reflect seasonal variation in infections. Although there were changes in donor selection and screening as well as cryopreservation patterns of donor products, no differences were observed across groups in 100-day overall survival, progression-free survival, rates of non–COVID-19 infections, including hospital length of stay, neutrophil engraftment, graft failure, acute graft-versus-host disease in allo-HSCT patients, or cytokine release syndrome and neurotoxicity in CAR-T patients. No HSCT patients contracted COVID-19 between days 0 and 100. One CAR-T patient contracted COVID-19 at day +51 and died of the disease. Altogether, our data indicate that cellular therapies can be safely administered throughout the ongoing COVID-19 pandemic with appropriate safeguards. •With sufficient resources, HSCT can safely continue in the COVID-19 pandemic if primary responsibility for COVID-19 patients is not required.•Cryopreservation of unrelated donor products correlated with slightly lower chimerism but no difference in clinical outcomes at 100 days. [Display omitted]